FRIDAY, March 20, 2015 (HealthDay News) -- Researchers have developed a new tool that may predict short-term glycemic progression to type 1 diabetes (T1D). The findings were published online March 10 in Diabetes Care.
Jay M. Sosenko, M.D., from the University of Miami, and colleagues utilized Diabetes Prevention Trial-Type 1 (DPT-1) data to develop and test a scale to serve as a potential end point for six-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D.
The researchers found that PS6M significantly predicted T1D (P < 0.001). Compared to the baseline-to-six-month difference in glucose, the area under the receiver operating characteristic curve was greater (P < 0.001) for the PS6M. In those with two or more autoantibodies, PS6M values were higher (30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00; P < 0.001 for all).
"The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers," the authors write.
Abstract
Full Text (subscription or payment may be required)
